Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, expectations were $-0.5. Operator: Good morning, everyone, and welcome to Verona Pharma’s Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
David Zaccardelli Sells 4,800 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock
CEO David Zaccardelli sold 4,800 shares of Verona Pharma stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $4.38, for a total transaction of $21,024.
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and
Verona Pharma Reports Strong Q3 Launch for COPD Drug
Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona
Raleigh pharma's stock hits record high amid drug launch
Verona Pharma's market cap nears $3 billion after drug launch. Ohtuvayre sales reached $5.6 million in the third quarter. Over 5,000 Ohtuvayre prescriptions filled by October's end. A Raleigh biopharmaceutical company is nearing a $3 billion market capitalization amid the launch of its lead drug.
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
Verona Pharma to Present at Jefferies London Healthcare Conference
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
ETF Daily News9d
Verona Pharma plc (NASDAQ:VRNA) Shares Sold by PFG Investments LLC
Get Our Latest Analysis on VRNA Verona Pharma Trading Down 1.7 % Shares of Verona Pharma stock opened at $33.86 on Monday. The company has a current ratio of 8.61, a quick ratio of 8.61 and a ...
Business Insider23h
Verona Pharma (VRNA) Receives a Buy from Truist Financial
Truist Financial analyst Joon Lee maintained a Buy rating on Verona Pharma (VRNA – Research Report) today. The company’s shares closed yesterday at $38.15. According to TipRanks, Lee is a 5-star ...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...
FiercePharma8d
After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...
Investing4d
Verona Pharma PLC ADR (VRNA)
At the close in NYSE,... ByInvesting.com • Mar 26, 2018 Verona Pharma's RPL554 shows treatment effect in mid-stage CF study; shares up 8% A UK-based Phase 2a clinical trial evaluating Verona ...